EP4 Deficiency in Macrophages Drives Atherosclerosis via CD36-Mediated Mechanisms

Study Background and Research Question

Atherosclerosis is a progressive vascular disorder characterized by the buildup of lipid-rich plaques within arterial walls, constituting the leading pathological basis for coronary artery disease, ischemic stroke, and peripheral vascular disease. Macrophages play a central role in atherogenesis by engulfing oxidized low-density lipoproteins (oxLDL), transforming into lipid-laden foam cells, and modulating inflammatory responses through phenotypic switching between M1 (pro-inflammatory) and M2 (anti-inflammatory) states. The signaling pathways that control macrophage polarization and lipid uptake remain incompletely understood, particularly in the context of prostaglandin E2 (PGE2) receptor signaling. The PGE2 receptor subtype 4 (EP4), which is highly expressed on macrophages, has been implicated in inflammation and lipid metabolism, but its specific role in atherosclerosis progression required further elucidation (Tang et al., 2025).

Key Innovation from the Reference Study

The study by Tang et al. introduces a critical mechanistic insight: macrophage-specific EP4 deficiency accelerates atherosclerosis by upregulating CD36, a scavenger receptor responsible for oxLDL uptake, and skewing macrophage polarization toward the pro-atherogenic M1 phenotype. This dual effect—enhanced lipid accumulation and pro-inflammatory activity—identifies EP4 as a pivotal control point linking prostaglandin signaling to the molecular events underpinning plaque progression (Tang et al., 2025).

Methods and Experimental Design Insights

The research employed a genetically engineered mouse model with myeloid-specific deletion of the EP4 receptor (EP4^ΔMye) in an ApoE-deficient (ApoE^-/-) background, a standard model for studying atherosclerosis. Mice were fed a Western diet for 16 weeks to induce robust plaque formation. In vivo analyses included assessment of aortic plaque area, histological plaque characterization, and immunostaining for macrophage markers. In vitro, primary macrophages were isolated and stimulated with oxLDL to dissect the molecular consequences of EP4 ablation on lipid uptake, foam cell formation, and polarization states. Transcriptomic and proteomic profiling, followed by qPCR and Western blot analyses, were used to confirm changes in CD36 expression and polarization markers (Tang et al., 2025).

Protocol Parameters

• assay | Myeloid-specific EP4 knockout (EP4^ΔMye) | confirmed by PCR genotyping | Ensures selective receptor deletion in macrophages | paper
• assay | ApoE-deficient background | standard for atherosclerosis modeling | Enhances plaque susceptibility | paper
• assay | Western diet | 16 weeks | Induces advanced atherosclerotic lesions | paper
• assay | oxLDL stimulation | 50 μg/mL, 24 h (in vitro) | Mimics in vivo lipid loading in macrophages | paper
• assay | Transcriptomic/proteomic analysis | post-stimulation | Identifies molecular pathways downstream of EP4 | paper
• assay | PCR master mix with dye reagents | as per manufacturer's instructions | Used for genotyping validation | workflow_recommendation

Core Findings and Why They Matter

The study’s core findings are threefold:

1. EP4 Downregulation in Atherosclerosis: EP4 expression was significantly reduced in both atherosclerotic plaques and oxLDL-stimulated macrophages, suggesting a loss of protective signaling during disease progression (Tang et al., 2025).
2. Promotion of Plaque Growth and Destabilization: Mice lacking macrophage EP4 exhibited larger atherosclerotic lesions and features characteristic of vulnerable plaques, indicating that EP4 signaling constrains both plaque expansion and destabilization (Tang et al., 2025).
3. Mechanistic Link to CD36 and M1 Polarization: Loss of EP4 led to increased CD36 expression, promoting lipid uptake and foam cell formation in macrophages, while also favoring M1 polarization. These effects were corroborated by transcriptomic, proteomic, and functional assays, positioning EP4 as a regulatory node connecting prostaglandin signaling, lipid metabolism, and inflammation (Tang et al., 2025).

These findings provide a mechanistic rationale for targeting EP4 or its downstream pathways as potential interventions in atherosclerosis.

Comparison with Existing Internal Articles

Several recent articles have focused on workflow optimization for mouse genotyping and the functional analysis of gene knockouts in disease models. For example, the article "Direct Mouse Genotyping Kit Plus: Rapid, High-Fidelity Mouse Genotyping" (internal article) highlights advances in rapid DNA extraction and PCR amplification without purification, which are essential for reliable colony management and genotype-phenotype correlation in complex studies like atherosclerosis. Similarly, "Direct Mouse Genotyping Kit Plus: Transforming Precision" (internal article) discusses the importance of robust genetic validation in macrophage lineage tracing—directly relevant to the knockout strategies used by Tang et al.

These resources underscore that high-throughput and accurate genotyping workflows, enabled by PCR master mixes with dye reagents and streamlined DNA extraction kits, are critical for the reproducibility and efficiency of cardiovascular genetics research, including the study of myeloid-specific gene deletions and their impact on disease phenotypes.

Limitations and Transferability

While Tang et al.'s study provides compelling evidence for the role of EP4 in macrophage-driven atherogenesis, several considerations merit attention:

• Species and Model Constraints: Findings are based on murine models and may not fully translate to human pathophysiology due to interspecies differences in immune response and lipid metabolism (Tang et al., 2025).
• Single Pathway Focus: The emphasis on CD36 may underrepresent other relevant lipid uptake and inflammatory pathways regulated by EP4.
• Timing and Reversibility: The study does not address whether restoring EP4 signaling in established disease could reverse or stabilize plaques, an important question for therapeutic translation.

Nonetheless, the genetic and molecular techniques applied are broadly transferable to other mouse models requiring gene knockout validation, transgene detection, or animal colony genetic screening (workflow_recommendation).

Research Support Resources

For research groups conducting mouse genotyping assays, transgene detection in mice, or gene knockout validation—particularly for studies investigating macrophage-specific gene functions—streamlined workflows are crucial. The Direct Mouse Genotyping Kit Plus (SKU K1027) provides a validated, purification-free protocol for genomic DNA extraction and direct PCR, supporting high-throughput and reproducible analysis of mouse models in cardiovascular and immunological research (workflow_recommendation). Its inclusion of a PCR master mix with dye reagents further expedites result interpretation during gel electrophoresis, aligning with the technical needs highlighted in both this reference study and internal workflow reviews.